Several academic laboratories and medical companies are rushing to produce these blood tests, which can quickly identify disease-fighting antibodies in people who already have been infected but may have had mild symptoms or none at all.
He is transferring the work to Mount Sinai’s clinical lab this week so it can begin testing patient samples.
Several private companies have begun selling blood tests for COVID-19 antibodies outside the United States, including California-based Biomerica and South Korean test maker Sugentech.
Meantime, at the Mayo Clinic in Rochester, Minnesota, researchers are preparing to start a clinical trial in which patients who test positive for COVID-19 would have their blood collected at the time of diagnosis, and again 15 to 20 days after that in the patient’s home.
Researchers at the Duke-National University of Singapore Medical School said they quickly developed one antibody test that had about 90 percent accuracy and later introduced a more sophisticated version that was more reliable, according to a report in the Straits Times of Singapore.